Oramed Pharmaceuticals Inc.

NasdaqCM:ORMP Stock Report

Market Cap: US$117.9m

Oramed Pharmaceuticals Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Nadav Kidron

Chief executive officer

US$1.7m

Total compensation

CEO salary percentage27.9%
CEO tenure18yrs
CEO ownership2.9%
Management average tenure11.3yrs
Board average tenure7.5yrs

Recent management updates

Recent updates

Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation

Aug 24
Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation

Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

May 03
Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth

Dec 22
Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth

Oramed: Oral Insulin For Type 2 Diabetes May Become A Reality

Sep 21

Oramed to hand Korean rights for insulin capsule

Sep 09

Oramed to report early-stage trial data for oral COVID-19 shot in 3Q

Jul 07

Is Oramed Pharmaceuticals (NASDAQ:ORMP) In A Good Position To Invest In Growth?

Jun 12
Is Oramed Pharmaceuticals (NASDAQ:ORMP) In A Good Position To Invest In Growth?

Oramed And Oral Insulin: Can This Small Company Really Do It?

Apr 14

Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth

Feb 23
Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth

Oramed And The Hurdles Of Developing Oral Insulin

Dec 23

Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation

Nov 02
Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation

Oramed: Prospects Still Remain Despite Merck-Ridgeback's Progress

Oct 04

We Think Shareholders Will Probably Be Generous With Oramed Pharmaceuticals Inc.'s (NASDAQ:ORMP) CEO Compensation

Aug 24
We Think Shareholders Will Probably Be Generous With Oramed Pharmaceuticals Inc.'s (NASDAQ:ORMP) CEO Compensation

Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

Jul 21
Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

Oramed reaches 50% enrollment in late-stage oral insulin study

Jun 08

Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

Apr 06
Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

The Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Is Up 110% And Shareholders Are Boasting About It

Feb 12
The Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Is Up 110% And Shareholders Are Boasting About It

Oramed Pharmaceuticals EPS beats by $0.42, revenue in-line

Jan 14

Why Oramed Pharmaceuticals' (NASDAQ:ORMP) CEO Pay Matters

Jan 08
Why Oramed Pharmaceuticals' (NASDAQ:ORMP) CEO Pay Matters

Oramed's obesity drug candidate shows decrease in glucose levels

Dec 23

We Think Oramed Pharmaceuticals (NASDAQ:ORMP) Can Afford To Drive Business Growth

Dec 04
We Think Oramed Pharmaceuticals (NASDAQ:ORMP) Can Afford To Drive Business Growth

Oramed launches late-stage NASH study with oral insulin

Dec 02

CEO Compensation Analysis

How has Nadav Kidron's remuneration changed compared to Oramed Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023US$2mUS$463k

US$6m

Sep 30 2023n/an/a

-US$16m

Jun 30 2023n/an/a

-US$20m

Mar 31 2023n/an/a

-US$30m

Dec 31 2022US$7mUS$491k

-US$37m

Sep 30 2022n/an/a

-US$46m

Jun 30 2022n/an/a

-US$46m

Mar 31 2022n/an/a

-US$40m

Dec 31 2021n/an/a

-US$35m

Nov 30 2021n/an/a

-US$25m

Aug 31 2021US$4mUS$466k

-US$22m

May 31 2021n/an/a

-US$18m

Feb 28 2021n/an/a

-US$15m

Dec 31 2020n/an/a

-US$22m

Nov 30 2020n/an/a

-US$15m

Aug 31 2020US$2mUS$439k

-US$12m

May 31 2020n/an/a

-US$11m

Feb 29 2020n/an/a

-US$13m

Nov 30 2019n/an/a

-US$13m

Aug 31 2019US$2mUS$419k

-US$14m

May 31 2019n/an/a

-US$15m

Feb 28 2019n/an/a

-US$15m

Nov 30 2018n/an/a

-US$14m

Aug 31 2018US$2mUS$436k

-US$13m

May 31 2018n/an/a

-US$12m

Feb 28 2018n/an/a

-US$10m

Nov 30 2017n/an/a

-US$10m

Aug 31 2017US$1mUS$400k

-US$10m

Compensation vs Market: Nadav's total compensation ($USD1.66M) is above average for companies of similar size in the US market ($USD661.05K).

Compensation vs Earnings: Nadav's compensation has been consistent with company performance over the past year.


CEO

Nadav Kidron (49 yo)

18yrs

Tenure

US$1,659,222

Compensation

Mr. Nadav Kidron, Esq. has been the Chief Executive Officer and President of Oramed Pharmaceuticals Inc. (Alternatively Integrated Security Technologies Inc) since March 08, 2006. Mr. Kidron served as an i...


Leadership Team

NamePositionTenureCompensationOwnership
Nadav Kidron
President18yrsUS$1.66m2.88%
$ 3.4m
David Silberman
CFO & Treasurer2.7yrsUS$536.71k0.22%
$ 264.5k
Miriam Kidron
Chief Scientific Officer & Director18yrsUS$1.11m0.21%
$ 250.7k
Joshua Hexter
Chief Operating & Business Officer4.5yrsUS$1.28m0.43%
$ 502.9k

11.3yrs

Average Tenure

51yo

Average Age

Experienced Management: ORMP's management team is seasoned and experienced (11.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Nadav Kidron
President18yrsUS$1.66m2.88%
$ 3.4m
Miriam Kidron
Chief Scientific Officer & Director18yrsUS$1.11m0.21%
$ 250.7k
Jay Skyler
Member of Scientific Advisory Board4.2yrsno datano data
Eleuterio Ferrannini
Member of Scientific Advisory Board17.1yrsno datano data
Harold Jacob
Member of Scientific Advisory Board7.3yrsUS$20.00kno data
Avram Hershko
Member of Scientific Advisory Board15.7yrsno datano data
G. Fleming
Member of Scientific Advisory Board4.3yrsno datano data
Leonard Sank
Independent Director16.4yrsUS$112.28k0.068%
$ 80.6k
Roy Eldor
Member of the Scientific Advisory Board7.7yrsno datano data
Anne Peters
Member of Scientific Advisory Board1.8yrsno datano data
Arie Mayer
Independent Director4.3yrsUS$127.28k0.064%
$ 75.1k
Julio Rosenstock
Member of Scientific Advisory Board4.2yrsno datano data

7.5yrs

Average Tenure

69yo

Average Age

Experienced Board: ORMP's board of directors are considered experienced (7.5 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.